Experimental combo aims to outsmart resistant lymphoma

NCT ID NCT06675123

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This early-phase trial tests whether combining two drugs—pacritinib and a BTK inhibitor—is safe and effective for people with mantle cell lymphoma that has come back or stopped responding to treatment. Ten adults will receive the combination and be monitored for side effects and tumor response. The goal is to find a new option for this hard-to-treat blood cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pacritinib combined with a BTK inhibitor
What this could lead to: If it works, this could point toward a new treatment option for patients with mantle cell lymphoma that has returned or not responded to prior therapy.
What could go wrong: This is a very early, small Phase 1 trial with only 10 participants, so results may not apply broadly. The main goal is safety, not yet proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT MANTLE CELL LYMPHOMA REFRACTORY MANTLE CELL LYMPHOMA

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.